Literature DB >> 12169517

Cost of nitric oxide is exorbitant.

C M Pierce, M J Peters, G Cohen, A P Goldman, A J Petros.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12169517      PMCID： PMC1123840          DOI： 10.1136/bmj.325.7359.336

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn.

Authors:  D L Wessel; I Adatia; L J Van Marter; J E Thompson; J W Kane; A R Stark; S Kourembanas
Journal:  Pediatrics       Date:  1997-11       Impact factor: 7.124

2.  Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group.

Authors:  J D Roberts; J R Fineman; F C Morin; P W Shaul; S Rimar; M D Schreiber; R A Polin; M S Zwass; M M Zayek; I Gross; M A Heymann; W M Zapol
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

3.  Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure.

Authors: 
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

4.  Cost implications of using inhaled nitric oxide compared with epoprostenol for pulmonary hypertension.

Authors:  A J Petros; S C Turner; A J Nunn
Journal:  J Pharm Technol       Date:  1995 Jul-Aug

5.  Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass.

Authors:  D L Wessel; I Adatia; T M Giglia; J E Thompson; T J Kulik
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690
  5 in total
  3 in total

1.  Nitric oxide is not licensed for preterm neonates.

Authors:  Charles E M Normand; David Field; Diana Elbourne; Ann Truesdale
Journal:  BMJ       Date:  2002-11-23

Review 2.  Antenatal hypoxia and pulmonary vascular function and remodeling.

Authors:  Demosthenes G Papamatheakis; Arlin B Blood; Joon H Kim; Sean M Wilson
Journal:  Curr Vasc Pharmacol       Date:  2013-09       Impact factor: 2.719

3.  Inhaled nitric oxide for the adjunctive therapy of severe malaria: protocol for a randomized controlled trial.

Authors:  Michael Hawkes; Robert O Opoka; Sophie Namasopo; Christopher Miller; Kevin E Thorpe; James V Lavery; Andrea L Conroy; W Conrad Liles; Chandy C John; Kevin C Kain
Journal:  Trials       Date:  2011-07-13       Impact factor: 2.279
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.